Exhausting, sweating, and fatigue are rare blood diseases that require early treatment and innovative therapy

Contemporary therapy reduces the risk of the disease's progress and enables longer life for patients, writes European Hematology Association and finds hematologists dealing with the treatment of summer police, a rare but manageable disease, of bone marrow.

What's the wine policy?

Summer policy (PV) is a chronic hematological mountain disease characterized by increased production of red blood cells in bone marrow.

According to Mayo Clinic and Cleveland Clinic, this situation causes blood to increase viscosity, making circulation more difficult, especially in small blood vessels, which increases the risk of forming trumpets.

The main cause is the mutation acquired in the JAK2 (V617F) gene, which is uncontrolled to activate cell sharing in the bone marrow. This is a mutation won, not inherited, so it doesn't go directly to the offspring, it transmits thegraphy.

Symptoms - They often appear years before diagnosis

Doctors note that warning signs may appear several years before the diagnosis is established. According to Leukemia & Lymphoma Society, the most common symptoms include:

Chronic fatigue, general sense of weakness;
The scratching of the body, by no means after the warm shower, because of the release of histamine;
Sacrificing at night, sometimes accompanied by weight loss;
Headache, dizziness, and sense of piercing;
Pressure or pain on the left of the abdomen resulting from the dilation of the soul.

These symptoms directly affect the quality of life, and according to studies published in Blood Advances, PV patients have shorter average life expectancy compared to the general population in the same age group if the disease is not treated properly.

Risks - Trumpets and Changes to More Serious Diseases

The wine policy belongs to the mineloplasm group <x0... The greatest danger is thrombosis (the formation of clots), which can lead to strokes, a miocard heart attack, or a thrombosis of deep veins.

In some cases, the disease can be transformed into mielofibrosis, a more aggressive form of blood cancer, where bone marrow tissue is replaced by fibrosis, preventing normal blood cell production.

According to the American Society of Hematology, about 1 in 4 patients with police, wine develops mielofibrosis within 15-20 years of diagnosis, especially if the disease is not treated with proper therapy.

Diagnosis and Treatment

The diagnosis is confirmed by laboratory blood analysis, bone marrow biopsy and genetic testing for the JAK2 mutation.

Standard treatment involves:

Frobotomi (blood drop): 300400 ml of blood is removed to lower hematocrit and prevent clots;
Hydroxiure (cystatic): reduces the production of blood cells;
Aspirin in low doses for anti-grombosis profile;
Controls of cardiovascular risk factors, such as high blood pressure, cholesterol, and tobacco ban.
Innovative therapy

According to European Medicines Agency (EMA) and FDA reports, the use of JAK2's inhybis (such as ruxholitinibi) has significantly changed the performance of the disease, especially in patients who do not respond to hydroxiure.

These drugs:

They lower the size of the throat,
Soften systemic symptoms (crowding, fatigue, etc).
They lower the risk of being transformed into mielophrose,
They extended the average life of patients.
In some Western European and US centres, new combinations of therapies (e.g. are also being tested. Ropeginterferons alpha-2bs, aimed at modification of the root of the disease at a cell level, not just its symptoms.

The Importance of Early Diagnosis and Long - Term Support

Hematologists stress that early discovery and personal treatment are key to preventing serious complications.

The earlier the wine police are identified, the greater the chance of the patient living long and quality of life”, states the prof. Dr. Heinz Gislinger of Vienna University, one of the leading experts on milopoluitive diseases.

Patient associations are also stressing the need for access to new therapies and the involvement of psychological and social support in patients' long-term care.

End

Summer policy is a chronic but manageable bone marrow disease.
With early diagnosis, careful hematological monitoring and modern therapy, a long and active life for most patients can be provided.

According to the Journal of Clinical Oncology, individualized treatment and multidisciplinary approach are the factors that today distinguish between a dangerous disease and a successfully controlled condition. /Periscopi/